CTLA4 and neoplasm: Another anti-CTLA-4 mAb, tremelimumab, was added to durvalumab/cisplatin/5-FU treatment where manageable safety and anti-tumour activity in patients with advanced or metastatic ESCC were shown (OR: 37.5%; mPFS: 3.75 months and mOS: 9.69 months; NCT02658214) [115], warranting further investigation in randomised trials.